Investor List:

Top Therapeutics Series B Investors in New York City (13)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Manufacturing (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Manufacturing (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Pablo Lubroth, Investor at Hummingbird Ventures
Pablo Lubroth
Sweet spot: $2.8M
Range: $500K - $5.0M
Investors in London, Investors in New York (NY)
Investors in Therapeutics (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in DeepTech (Pre-seed), Investors in BioTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in Therapeutics (Seed), Investors in DeepTech (Seed), Investors in Digital Health (Seed), Investors in Therapeutics (Seed), Investors in DeepTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in DeepTech (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Therapeutics (Series A), Investors in DeepTech (Series A), Investors in Therapeutics (Series A), Investors in Digital Health (Series A), Investors in DeepTech (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Pharmaceuticals (Series A), Investors in DeepTech (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series B), Investors in DeepTech (Series B), Investors in Therapeutics (Series B), Investors in DeepTech (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Pharmaceuticals (Series B), Investors in DeepTech (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in London (Other Lists), Investors in New York City (Other Lists)
Photo of Dan Becker, Managing Director at Access Biotechnology
Dan Becker
Access Biotechnology·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Mateo (CA), Investors in New York (NY)
Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in BioTech (Series B), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Joyce Erony, Managing Partner at Amzak Health Investors
Joyce Erony
Amzak Health Investors·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York City
Investors in Therapeutics (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in BioTech (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in BioTech (Pre-seed), Investors in Therapeutics (Seed), Investors in Medical Devices (Seed), Investors in Therapeutics (Seed), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Medical Devices (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in BioTech (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in New York City (Other Lists)
Photo of Uya Chuluunbaatar, Principal at Amzak Health Investors
Uya Chuluunbaatar
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York City
Investors in Therapeutics (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Pre-seed), Investors in Therapeutics (Seed), Investors in Medical Devices (Seed), Investors in Therapeutics (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Medical Devices (Seed), Investors in Digital Health (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed), Investors in Therapeutics (Series A), Investors in Medical Devices (Series A), Investors in Therapeutics (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Medical Devices (Series B), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in New York City (Other Lists)
RM
Rob Morrow
Thiel Capital·Principal
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)
Photo of Tim Schlidt, Partner at Palo Santo VC
Tim Schlidt
Palo Santo VC·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)
Photo of Zach Lomis, Partner at Palo Santo VC
Zach Lomis
Palo Santo VC·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)